Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$48.05 USD
+1.09 (2.32%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $48.09 +0.04 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Agios Pharmaceuticals, Inc. [AGIO]
Reports for Purchase
Showing records 141 - 160 ( 306 total )
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Agios Files MAA With EMA a Bit Ahead of Expectations
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Agios Submits NDA for Mitapivat a Bit Earlier Than Expected, But Anticipate Minimal Impact on Stock Price
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended June 18
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Additional Thoughts on Mitapivat Post EHA Conference Call; Reiterate Buy at $88 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Agios Reports Positive Phase 2 and 3 mitapivat Data at EHA2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended June 11
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Initiating Coverage With a Buy Rating and $88 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended May 14
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended May 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended April 30
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended April 23
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended April 16
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended April 9
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 12
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D